| Host: |
HEK293 cells NA |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-HLA-A*011:01 KRAS G12D peptide complex is synthetically produced from the Human HLA-A*011:01 AA25-305/B2M protein AA2-119 sequence and is suitable for use in western blot applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4 NA |
| Dilution Range: |
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. NA |
| Storage Instruction: |
The lyophilized protein is stable for at least 2 years from date of receipt at-20°C C. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunogen Region: |
Human HLA-A*011:01 AA25-305/B2M protein AA2-119 |
| Accession Number: |
P61769 |
| Immunogen: |
DNA sequence encoding the Human (HLA-A*011:01) AA25-305 [accession# P04439] and the B2M protein AA2-119 [accession# P61769], fused to the mutant G12D KRAS epitope VVVGADGVGK.This complex includes a C terminal polyHis and was expressed in HEK cells. N |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
